"The Report Breast Cancer
Therapeutics in Southeast Asia Markets to 2022 - Increasing
Prevalence and Usage of Premium Targeted Therapies to Drive the
Market provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Already a multi-billion dollar
industry, the breast cancer therapeutics market in Southeast Asia is
expected to surpass its current value considerably by 2022. With
Southeast Asia witnessing a rapid incidence of breast cancer, nations
are compelled to focus on research and development of novel
therapeutics. MarketResearchReports.biz has announced the addition of
a market study delving into prospects for the breast cancer
therapeutics market in Southeast Asia. The report is titled, “Breast
Cancer T herapeutics In Southeast Asia Markets
To 2022 - Increasing Prevalence And Usage Of Premium Targeted
Therapies To Drive The Market,” and is available for sale on the
company website.
According to WHO, breast cancer
has become the second most common type of disease affecting millions
globally. While the U.S., EU, and Australia are known to report a
high prevalence of the ailment, the number of patients ailing for the
same has increased in Southeast Asia as well. Currently the Southeast
breast cancer therapeutics market comprises hormonal therapies
chemotherapies, and other targeted therapies. Herceptin is a gold
standard monoclonal antibody, which is commonly prescribed for
treating HER2-assessed countries. However, its use in Southeast Asian
countries has remained restricted owing to limitations in the
diagnosis of HER2 status and persisting affordability issues.
In addition, Southeast Asian
countries are witnessing the high prevalence of unmet need in
treatment options for triple negative breast cancer. These countries
have continued depending on chemotherapies for the treatment, which
again are limited in terms of toxicity and efficacy. The demand for
effective treatment is therefore quite high in Southeast Asia.
However, the market has witnessed increased uptake of various premium
branded drugs and targeted therapies in countries such as South
Korea, Taiwan, and Singapore.
Get Sample Copy Of this Report
@
Premium therapies such as Perjeta
and Kadcyla are yet to be approved in Thailand, Indonesia, Malaysia,
and Vietnam. Despite lower scope for sales of these drugs, they will
continue holding a substantial share in Southeast Asia breast cancer
therapeutics market due to their superior quality, high efficacy, and
high price. Also in a few years, when these drugs are approved in the
aforementioned nations, their share in the overall market will
increase further.
Besides Kadcyla and Perjeta, the
Southeast Asia breast cancer therapeutics market comprises CDK
inhibitors such as Ibrance and tyrosine kinase inhibitors such as
Tykerb. Growth in the sales of these drugs will therefore up
Southeast Asia’s share in the overall breast cancer therapeutics
market. The report presents a thorough analysis of various factors
supporting the market’s expansion in Southeast Asia. Policies and
behavior of governments toward these targeted therapies are studied
for individual Southeast Asian countries. Besides this, the report
also presents insights into factors leading to high demand for a
particular drug from a given country.
View Press Release @
http://www.marketresearchreports.biz/pressrelease/4584
The report also presents a
detailed analysis of the marketed drugs and those, which are in
pipeline. It is therefore compiled to help stakeholders gain a better
perspective of the Southeast Asia breast cancer therapeutics market.
Toward the end, the report studies the competition prevailing in the
market by profiling some of the leading players operating therein.
Their individual market share is calculated in the report as well.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment